<DOC>
	<DOC>NCT00496353</DOC>
	<brief_summary>The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461. The purpose of the phase II portion is to evaluate the anti-tumor efficacy of MK2461.</brief_summary>
	<brief_title>MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>Patients must be at least 18 years of age, with adequate organ function, and an ecog performance of &lt;2 No chemotherapy, radiotherapy, or biological therapy with 4 weeks of study participation Patients must not have primary central nervous system tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neoplasm Malignant</keyword>
</DOC>